About Us

Tianjin Orilife Biopharma Co.,Ltd.

Tianjin Orilife Biopharma Co.,Ltd. is an enterprise engaged in the research, production, and sales of modified nucleosides, nucleotides, phosphoramidites, nucleic acid drug synthesis carriers, nucleic acid drug delivery carriers, and auxiliary materials for nucleic acid drug synthesis.

  • 50+

    Reaction Kettles

  • 6000kg

    Designed Production Capacity

  • 30Years

    Research and Development Experience

PRODUCT

Phosphoramidites

Nucleosides/ Protected Nucleosides

Nucleotide

DNA/RNA synthesis solvents

GalNAc carrier/High capacity systhesis carrier

See More

See More
Application Area Orilife provides raw materials for the small nucleic acid drug industry, which has a rich pool of candidate targets, a wide range of indications, and great application potential.
Small nucleic acid drugs are pharmaceuticals composed of artificially chemically synthesized short ribonucleotides, either single-stranded or double-stranded. They act on messenger RNA through the Watson-Crick base pairing principle. Compared to traditional drugs, small nucleic acid drugs have significant advantages in candidate targets, design, specificity, efficacy, and clinical development success rate. Coupled with the maturity of RNAi technology, small nucleic acid drugs are expected to have extensive applications in the fields of oncology and rare diseases, potentially improving the accessibility of medications for rare disease patients.
Customized Product Factory visits are welcomed
We can provide custom synthesis of DNA/RNA monomers, accepting orders from milligram to kilogram quantities.
01 R&D Strength

+
02 Application Area

+
03 Customized Product

+

Development History

August 2020
Rianlon and GenePharma collaborate on the project of 'Small Nucleic Acid Drug Raw Materials'.
December 2020
Rianlon Life Sciences Division has been officially established.
13 April 2021
Tianjin Orilife Biopharma Co., Ltd. is established, and Rianlon collaborates with GenePharma to enter the field of small nucleic acid drug raw materials.
30 September 2022
Orilife's nucleic acid monomer pilot development project has passed the acceptance inspection.
December 2022
Orilife’s nucleic acid monomer trial production.
August 2020
December 2020
April 2021
September 2022
December 2022

NEWS

News

  • Company News
  • Industry News
  • Announcements
15032236037
  • wangtongtong@cnorilife.com
  • 8 Huangshan Road, Hangu Modern Industrial Park, Tianjin, China
Share

ABOUT US

PRODUCT

SUPPORT & SERVICE

NEWS

CONTACT US

WeChat official account
Tianjin Orilife Biopharma Co., Ltd. All rights reserved.

津ICP备2023004375号